1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Human Papillomavirus Infections Global Clinical Trials Review, H2, 2014

Human Papillomavirus Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Human Papillomavirus Infections Global Clinical Trials Review, H2, 2014" provides data on the Human Papillomavirus Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Human Papillomavirus Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Human Papillomavirus Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Human Papillomavirus Infections Global Clinical Trials Review, H2, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Human Papillomavirus Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Human Papillomavirus Infections 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Human Papillomavirus Infections Therapeutics Clinical Trials 31
Prominent Drugs 32
Latest Clinical Trials News on Human Papillomavirus Infections 33
Nov 18, 2014: Researchers Pioneer New Approach To Treating HPV-Related Cervical Cancer 33
Nov 13, 2014: Genticel completes ProCervix Phase II study enrollment ahead of schedule 34
Nov 04, 2014: Cevira data published in American Journal of Obstetrics and Gynecology 34
Oct 30, 2014: Genexine's HPV Therapeutic Vaccine Achieved High Efficacy in Phase I Cervical Dysplasia Trial 35
Oct 10, 2014: Results of the Cevira Phase 2b presented at DGGG 35
Oct 08, 2014: Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine 36
Sep 22, 2014: Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 36
Clinical Trial Profiles 38
Clinical Trial Overview of Top Companies 38
Merck and Co., Inc. 38
Clinical Trial Overview of Merck and Co., Inc. 38
GlaxoSmithKline plc 43
Clinical Trial Overview of GlaxoSmithKline plc 43
Medicis Pharmaceutical Corporation 48
Clinical Trial Overview of Medicis Pharmaceutical Corporation 48
BioMAS Ltd. 49
Clinical Trial Overview of BioMAS Ltd. 49
AstraZeneca PLC 50
Clinical Trial Overview of AstraZeneca PLC 50
Novartis AG 51
Clinical Trial Overview of Novartis AG 51
MediGene AG 52
Clinical Trial Overview of MediGene AG 52
Meda AB 53
Clinical Trial Overview of Meda AB 53
Genticel S.A. 54
Clinical Trial Overview of Genticel S.A. 54
GandE Herbal Biotechnology Co., Ltd. 55
Clinical Trial Overview of GandE Herbal Biotechnology Co., Ltd. 55
Clinical Trial Overview of Top Institutes / Government 56
The National Institute of Allergy and Infectious Diseases 56
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 56
National Cancer Institute 57
Clinical Trial Overview of National Cancer Institute 57
Johns Hopkins University 58
Clinical Trial Overview of Johns Hopkins University 58
University of Pittsburgh 59
Clinical Trial Overview of University of Pittsburgh 59
The University of Hong Kong 60
Clinical Trial Overview of The University of Hong Kong 60
Leiden University Medical Center 61
Clinical Trial Overview of Leiden University Medical Center 61
Medical University of Vienna 62
Clinical Trial Overview of Medical University of Vienna 62
AIDS Malignancy Clinical Trials Consortium 63
Clinical Trial Overview of AIDS Malignancy Clinical Trials Consortium 63
The Alfred Hospital 64
Clinical Trial Overview of The Alfred Hospital 64
The University of Sydney 65
Clinical Trial Overview of The University of Sydney 65
Five Key Clinical Profiles 66
Appendix 99
Abbreviations 99
Definitions 99
Research Methodology 100
Secondary Research 100
About GlobalData 101
Contact Us 101
Disclaimer 101
Source 101

List of Tables
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Human Papillomavirus Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Human Papillomavirus Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Human Papillomavirus Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Human Papillomavirus Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Human Papillomavirus Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Human Papillomavirus Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Human Papillomavirus Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Human Papillomavirus Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Human Papillomavirus Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Human Papillomavirus Infections Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Human Papillomavirus Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Human Papillomavirus Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Human Papillomavirus Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 29
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 38
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 43
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Medicis Pharmaceutical Corporation, 2014* 48
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by BioMAS Ltd., 2014* 49
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 50
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 51
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by MediGene AG, 2014* 52
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Meda AB, 2014* 53
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Genticel S.A., 2014* 54
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GandE Herbal Biotechnology Co., Ltd., 2014* 55
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 56
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 57
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2014* 58
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 59
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Hong Kong, 2014* 60
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 61
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2014* 62
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AIDS Malignancy Clinical Trials Consortium, 2014* 63
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The Alfred Hospital, 2014* 64
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2014* 65

List of Figures
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Human Papillomavirus Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Human Papillomavirus Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Human Papillomavirus Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Human Papillomavirus Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Human Papillomavirus Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Human Papillomavirus Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Human Papillomavirus Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Human Papillomavirus Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Human Papillomavirus Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Human Papillomavirus Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 29
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 100

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.